Je was op zoek naar: teratogeniskas (Lithouws - Engels)

· kad lenalidomidas gali bti teratogeniskas
· that lenalidomide may be teratogenic

nateglinidas nebuvo teratogeniskas ziurkms.
nateglinide was not teratogenic in rats.

ambrisentanas teratogeniskas ziurkms ir pelms.
ambrisentan has been shown to be teratogenic in rats and mice.

22 nustatyta, kad duodant bevacizumabo triusiams, jis buvo embriotoksiskas ir teratogeniskas.
bevacizumab has been shown to be embryotoxic and teratogenic when administered to rabbits.

tyrim su gyvnais metu nestebtas teratogeniskas ar koks nors poveikis moter bei vyr vaisingumui.
reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility.

ziurkms lenalidomidas nebuvo teratogeniskas esant geriamoms dozms iki 500 mg/kg/par.
in rats, lenalidomide was not teratogenic at oral doses of up to 500 mg/kg/day.

giminingas razoksanas buvo embriotoksiskas pelms, ziurkms ir triusiams, taip pat teratogeniskas ziurkms ir pelms.
the related razoxane has been demonstrated to be embryotoxic in mice, rats and rabbits and teratogenic in rats and mice.

beksarotenas, kaip ir kiti retinoidai, teratogeniskas ir embriotoksiskas gyvnams, jeigu skiriamas ekvivalentiskomis zmogui dozmis.
bexarotene, in common with the majority of retinoids, was teratogenic and embryotoxic in an animal test species at systemic exposures that are achievable clinically in humans.

rotigotinas nebuvo teratogeniskas visoms trims rsims, taciau buvo embriotoksiskas ziurkms bei pelms, esant nscioms patelms toksinms dozms.
rotigotine was not teratogenic in all three species, but was embryotoxic in rats and mice at materno-toxic doses.

ilgalaikiai lamivudino kancerogeniskumo su ziurkmis ir pelmis tyrimai neparod jo kancerogeninio potencialo.tyrim su gyvnais metu nestebtas teratogeniskas ar koks nors poveikis moter bei vyr vaisingumui.
reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility.

manoma, kad sistemin ekspozicija ranibizmabui vartojant jo akis yra labai maza, taciau dl savo veikimo mechanizmo ranibizumabas turi bti laikomas galimai teratogeniskas ir pasizymintis toksiniu poveikiu embrionui bei vaisiui.
the systemic exposure to ranibizumab is expected to be very low after ocular administration, but due to its mechanism of action, ranibizumab must be regarded as potentially teratogenic and embryo-/foetotoxic.

deferasiroksas nebuvo teratogeniskas, bet didino skeleto vystymosi sutrikim ir negyv jaunikli dazn, kai ziurki patelms, kurioms nebuvo gelezies pertekliaus, buvo duodamos didels, sunki toksini reiskini sukeliancios dozs.
deferasirox was not teratogenic, but caused increased frequency of skeletal variations and stillborn pups in rats at high doses that were severely toxic to the non-iron-overloaded mother.

imatinibas, kurio organogenezs laikotarpiu buvo skiriama 100 mg/kg (mazdaug atitinka pagal kno pavirsiaus plot apskaiciuot didziausi klinikin 800 mg per par doz) , buvo teratogeniskas ziurkms.
imatinib was teratogenic in rats when administered during organogenesis at doses 100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.

olanzapinas neveik teratogeniskai.
olanzapine had no teratogenic effects.